GRISEOFULVIN,ULTRAMICROSIZE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Griseofulvin,ultramicrosize, and when can generic versions of Griseofulvin,ultramicrosize launch?
Griseofulvin,ultramicrosize is a drug marketed by Sigmapharm Labs Llc and is included in one NDA.
The generic ingredient in GRISEOFULVIN,ULTRAMICROSIZE is griseofulvin, ultramicrosize. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the griseofulvin, ultramicrosize profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Griseofulvin,ultramicrosize
A generic version of GRISEOFULVIN,ULTRAMICROSIZE was approved as griseofulvin, ultramicrosize by MOUNTAIN on January 9th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GRISEOFULVIN,ULTRAMICROSIZE?
- What are the global sales for GRISEOFULVIN,ULTRAMICROSIZE?
- What is Average Wholesale Price for GRISEOFULVIN,ULTRAMICROSIZE?
Summary for GRISEOFULVIN,ULTRAMICROSIZE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for GRISEOFULVIN,ULTRAMICROSIZE |
| DailyMed Link: | GRISEOFULVIN,ULTRAMICROSIZE at DailyMed |
Pharmacology for GRISEOFULVIN,ULTRAMICROSIZE
| Drug Class | Tubulin Inhibiting Agent |
| Physiological Effect | Decreased Mitosis Microtubule Inhibition |
US Patents and Regulatory Information for GRISEOFULVIN,ULTRAMICROSIZE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sigmapharm Labs Llc | GRISEOFULVIN,ULTRAMICROSIZE | griseofulvin, ultramicrosize | TABLET;ORAL | 202545-001 | Oct 22, 2012 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sigmapharm Labs Llc | GRISEOFULVIN,ULTRAMICROSIZE | griseofulvin, ultramicrosize | TABLET;ORAL | 202545-002 | Oct 22, 2012 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
